CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Search Results

Now showing 1 - 10 of 44

Some of the metrics are blocked by your
consent settings
Tackling cutaneous herpes simplex virus disease with topical immunomodulators—a call to action
(American Society for Microbiology, 2025-03-13)
DUARTE PEÑALOZA, LUISA FERNANDA
;
Javier Carbone-Schellman
;
Susan M. Bueno
;
Alexis M. Kalergis
;
Claudia A. Riedel
Antivirals play important roles in restricting viral diseases. Nevertheless, they act on a relatively limited number of viruses and occasionally display partial effectiveness in some tissues or against escape variants. Although vaccination remains the most cost-effective approach for preventing microbial diseases, developing prophylactic or therapeutic solutions for pathogens, such as herpes simplex viruses (HSVs), that effectively reduce their clinical manifestations in the skin has proven exceptionally challenging despite extensive research. Alternatively, a less explored approach for tackling HSV skin infection involves using topical immunomodulatory molecules to potentiate the host’s innate antiviral immune responses. When applied directly to herpetic skin lesions where viral antigen is present, this strategy has the potential to elicit virus-specific adaptive immunity. Based on currently available data, we foresee substantial potential for this approach in addressing HSV skin infections, along with additional prospects to advance understanding of skin biology and apply relevant new findings to other dermatological conditions. However, due to the limited number of case studies evaluating this method and its safety profile, particularly in immunocompromised individuals and pregnant women, further research is crucial, especially to assess the effects of immunomodulators in these vulnerable populations. Here, we revisit and discuss the use of immunomodulatory molecules for potentiating the host immune response against HSV skin infection and call for action for increased research and clinical trials regarding the possible benefits of this latter strategy for treating HSV cutaneous disease and recurrences. We also revisit and discuss antivirals and vaccine candidates against HSVs.
Scopus© Citations 2 7
Some of the metrics are blocked by your
consent settings
Myocardial perfusion imaging in advanced coronary artery disease
(Wiley, 2025-03-18)
Roel Hoek
;
Pepijn A. van Diemen
;
Yvemarie B. O. Somsen
;
Ruben W. de Winter
;
Ruurt A. Jukema
Myocardial perfusion imaging (MPI) is widely adapted as a noninvasive technique to assess the presence and extent of ischemia in patients with symptoms suggestive of obstructive coronary artery disease (CAD). However, as CAD advances, several factors can complicate the interpretation of MPI, subsequently impacting clinical decision‐making. This review focuses on the utility of MPI by means of cardiac magnetic resonance (CMR) imaging, single‐photon emission computed tomography (SPECT) and positron emission tomography (PET) in patients with advanced CAD—the latter characterized by documented CAD (i.e. prior myocardial infarction [MI] and/or percutaneous coronary intervention [PCI]), prior coronary artery bypass grafting (CABG) or the presence of a chronic total occlusion (CTO). It will discuss factors impacting the interpretation of MPI, the diagnostic performance for detecting obstructive CAD and coronary microvascular dysfunction (CMD), as well as the role of MPI in guiding revascularization.
Scopus© Citations 1 2
Some of the metrics are blocked by your
consent settings
Tumor hypoxia shapes natural killer cell anticancer activities
(Springer Science and Business Media LLC, 2025-05-30)
RETAMAL LUCERO, MAURICIO ANTONIO
;
Flavio Salazar-Onfray
;
Fermín E. González
;
Andrés Tittarelli
1
Some of the metrics are blocked by your
consent settings
Cultural Semiotic Model for Psychotherapy
(Springer Science and Business Media LLC, 2025-02-20)
MOLINA PAVEZ, MARIA ELISA
;
Raffaele De Luca Picione
;
María Teresa del Rio
;
Linus P. F. Guenther
;
Augusto Mellado
Scopus© Citations 3 8
Some of the metrics are blocked by your
consent settings
Retrospective study on disparities in time-to-treatment by health insurance system in Chilean breast cancer patients
(Medwave Estudios Limitada, 2025-04-10)
ACEVEDO ROMO, JOHANNA PATRICIA
;
Teresa Ip
;
Lea Maureira
;
Cesar Sanchez
;
Claudia Osorio
Introduction Breast cancer is the most common malignancy in the Americas, and the second leading cause of cancer death. Disparities in the time to treatment can significantly impact patient outcomes and typically affect lower socioeconomic individuals and/or ethnic minorities. Our study sought to evaluate disparities in time to treatment at three health institutions in Chile according to their type of health insurance (public or private). Methods Our study analyzed a database of breast cancer patients diagnosed between 2017 and 2018. Analyses included descriptive statistics and a linear regression model that incorporated clinical and demographic variables. Additionally, using a proportional risks model, we analyzed the association between clinical variables and mortality. Results Public health insurance (National Health Fund, FONASA) was associated with longer time-to-treatment and extended treatment times versus private health insurance (Social Security Institutions, ISAPRE; p < 0.0001). As expected, a more advanced stage at diagnosis was associated with lower survival. Our proportional risks model found that age was a predictor of breast cancer mortality in stage II patients. Also, total treatment time significantly increased the risk of breast cancer mortality in stage I patients. Conversely, total treatment time did not affect mortality on stages II or III. Conclusions We found significant disparities in the time to treatment of Chilean breast cancer patients using FONASA versus private ISAPRE. FONASA patients experience delays in the initiation of treatment and longer total treatment times compared to their private insurance counterparts. Finally, longer time-to-treatment was associated with more advanced stages and increased mortality.
3
Some of the metrics are blocked by your
consent settings
Latin America Cutaneous Oncology Management (LACOM) I: The Role of Skin Care in Oncology Patients and Survivors
(SanovaWorks, 2025-02-01)
Daniel Alcalá Pérez
;
Ana Sofia Acosta Madiedo
;
Sebastian Andreani
;
Anneke Andriessen
;
Hebert Cárdenas
2
Some of the metrics are blocked by your
consent settings
Neuromyelitis optica spectrum disorder in Latin America: a global data share initiative
(Elsevier BV, 2025-06)
Juan I. Rojas
;
Liliana Patrucco
;
Edgardo Cristiano
;
José I. Gortari
;
Paola A. Ortiz Salas
Scopus© Citations 2 1
Some of the metrics are blocked by your
consent settings
Barriers to accessing formal cancer care from the perspective of informal caregivers: a qualitative study
(Springer Science and Business Media LLC, 2025-04-21)
CAMPAÑA, CARLA
;
CABIESES VALDES, BALTICA BEATRIZ
;
OBACH KING, ALEXANDRA ALICE
;
Francisca Vezzani
;
Angela Estay
5
Some of the metrics are blocked by your
consent settings
Efficacy of platelet-rich-fibrin for the treatment of alveolar osteitis: a systematic review and meta-analysis
(Medicina Oral, S.L., 2025)
C. Ávila-Oliver
;
V. Veloso
;
G. Laissle
;
AM. Rojas
;
F. Verdugo-Paiva
2
Some of the metrics are blocked by your
consent settings
Top ten research priorities in global burns care: findings from the James Lind Alliance Global Burns Research Priority Setting Partnership
(Elsevier BV, 2025-06)
Hollie Sarah Richards
;
Robert M T Staruch
;
Suzannah Kinsella
;
Jelena Savovic
;
Riaz Qureshi
Scopus© Citations 27 2

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results